Britain and America have forged a major trade agreement that will maintain no levies on British pharmaceutical products going into the American market.
Key Provisions of the Accord
Under the terms of the agreement, the UK has agreed to increase funding on medicines through the public health system. This commitment guarantees that import taxes on these vital products will be held at zero for a period of 36 months.
This deal comes after earlier threats to dramatically increase import taxes on branded pharmaceutical products, with increases floated reaching 100%.
"This deal between the Britain reinforces the global environment for cutting-edge drugs and establishes much-needed fairness to transatlantic pharmaceutical trade," a statement declared.
Commercial Impact
Drugs represent one of the the United Kingdom's most significant exports to the America, which is easily the biggest market for major British pharmaceutical firms.
Export figures indicate that in the year to the end of the third quarter, the UK shipped drugs worth billions to the US. This amount represented 17.4% of all goods exports in that timeframe.
"This deal safeguards work, stimulates capital expenditure and sets the stage for the UK to become a worldwide center for medical research," a government official commented.
Detailed NHS Changes
The agreement entails several specific changes from the UK:
- Price Threshold Increase: The UK will raise the cost ceiling at which it judges new medicines to be prohibitively costly by a quarter.
- Higher Drug Budget: There is a aim to raise overall public funding on treatments from 0.3% of GDP to 0.6 percent over the coming ten years.
- Payback Limit: The amount drug companies must refund to the NHS to prevent overspending will be limited at fifteen percent. In the past, repayments exceeded 20%.
Broader Context
This agreement takes place against a ongoing tension between the drug companies and the British authorities over medicine costs and NHS adoption.
These tensions were heightened by claims that US patients were charged several times more for the same drugs than patients in the Britain and the EU.
Over the last 18 months, several significant manufacturing plans in the UK have been halted or cancelled, while substantial investments have been pledged toward American operations.
The Science Minister acknowledged that the NHS must increase expenditure on treatments, noting that its expenditure on drugs had shrunk as a percentage of its total funding over the last ten years.
